Finoriq research workspace

ADMA BIOLOGICS, INC. (ADMA) Company Overview

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty. Review ADMA filings, fundamentals, valuation, and ownership on Finoriq.

Company Snapshot

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Company

ADMA BIOLOGICS, INC. (ADMA)

Ticker

ADMA

Market Cap

$2B

Latest Price

$8.79

Industry

Biotech & Pharma

Open insider transactions

ADMA BIOLOGICS, INC. (ADMA) Current Valuation Metrics

Static valuation preview for ADMA BIOLOGICS, INC. (ADMA). Market data retrieved 2026-07-08. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.